Mizuho raised the firm’s price target on Alkermes (ALKS) to $45 from $40 and keeps an Outperform rating on the shares. The firm views the acquisition of Avadel (AVDL) as “strategically synergistic.” The deal positions Alkermes as a leading player in sleep medicine, the analyst tells investors in a research note. Mizuho does not believe the timing of the deal signals Alkermes is losing confidence in the alixorexton program. It still expects competitive data in November.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Avadel downgraded to Neutral from Buy at H.C. Wainwright
- Alkermes’ Acquisition of Avadel: Strategic Potential Amid Market Uncertainty
- Alkermes price target raised to $45 from $38 at Piper Sandler
- Alkermes price target raised to $47 from $45 at RBC Capital
- Alkermes’ Strategic Acquisition of Avadel Pharmaceuticals Enhances Position in Sleep Disorder Market